Experience

180 Life Sciences

• Biotechnology Research
• 1 - 100 Employee

• Founder and Chief Scientific Officer 180 Life Sciences

  • Jan 2019 - Present



Lumen Pharmaceuticals

• Palo Alto

• Founder, and Board Director

  • Sep 2007 - Present

  Developed a method to improve patency of vein grafts in cardiac bypass surgery, which has been validated in human Phase 1/2 clinical trials. Developed a method to improve patency of vein grafts in cardiac bypass surgery, which has been validated in human Phase 1/2 clinical trials.



Katexco Pharmaceuticals

• Toronto, Canada, Palo Alto, CA, USA

• Chief Executive Officer

  • Aug 2018 - Jan 2019

  Katexco is developing orally available, small molecules as agonists for a7 nicotinic acetylcholine receptors and the cannabis CB2 receptor for reduction of inflammation in a variety of indications. Katexco is developing orally available, small molecules as agonists for a7 nicotinic acetylcholine receptors and the cannabis CB2 receptor for reduction of inflammation in a variety of indications.



Stanford University

• United States
• Higher Education
• 700 & Above Employee

• Sr. Research Scientist

  • Sep 2008 - Aug 2018

  exploring the utility of small heat shock proteins and amyloidogenic peptides as anti-inflammatory therapeutics to modulate the symptoms of EAE, ischemia reperfusion injury, type I diabetes, and stroke. exploring the utility of small heat shock proteins and amyloidogenic peptides as anti-inflammatory therapeutics to modulate the symptoms of EAE, ischemia reperfusion injury, type I diabetes, and stroke.



Medlogics Device Corporation

• Medical Device
• 1 - 100 Employee

• Scientific Director

  • Sep 2006 - Sep 2007

  Led a group of four research scientists that successfully developed a robust, scaleable method to manufacture drug eluting coronary stents using silica based sol-gels. The composition of the sol-gel can be chosen to modulate the release of a variety of therapeutic drugs, which markedly differ in their water solubility, from paclitaxel to peptide hormones. The coatings are capable of retaining therapeutic levels of the drugs, but also bioerode over a period of weeks, resulting in a bare metal… Show more Led a group of four research scientists that successfully developed a robust, scaleable method to manufacture drug eluting coronary stents using silica based sol-gels. The composition of the sol-gel can be chosen to modulate the release of a variety of therapeutic drugs, which markedly differ in their water solubility, from paclitaxel to peptide hormones. The coatings are capable of retaining therapeutic levels of the drugs, but also bioerode over a period of weeks, resulting in a bare metal stent. The technology entered a successful human trials in the third quarter of 2007. Show less Led a group of four research scientists that successfully developed a robust, scaleable method to manufacture drug eluting coronary stents using silica based sol-gels. The composition of the sol-gel can be chosen to modulate the release of a variety of therapeutic drugs, which markedly differ in their water solubility, from paclitaxel to peptide hormones. The coatings are capable of retaining therapeutic levels of the drugs, but also bioerode over a period of weeks, resulting in a bare metal… Show more Led a group of four research scientists that successfully developed a robust, scaleable method to manufacture drug eluting coronary stents using silica based sol-gels. The composition of the sol-gel can be chosen to modulate the release of a variety of therapeutic drugs, which markedly differ in their water solubility, from paclitaxel to peptide hormones. The coatings are capable of retaining therapeutic levels of the drugs, but also bioerode over a period of weeks, resulting in a bare metal stent. The technology entered a successful human trials in the third quarter of 2007. Show less



Stanford University

• United States
• Higher Education
• 700 & Above Employee

• Senior Scientist

  • Sep 2004 - Sep 2006

  In collaboration with Dr. Paul Wender established a real time assay monitoring the release of prodrugs inside cells and in animals. This program solves one of the key problems that led to dissolution of the research and clinical program at CellGate using prodrugs with arginine rich transporters. Currently establishing that short oligomers of arginine can used to deliver small molecules, oligonucleotides and single antibodies to the liver as therapeutic agents for hepatitis and the eye to treat… Show more In collaboration with Dr. Paul Wender established a real time assay monitoring the release of prodrugs inside cells and in animals. This program solves one of the key problems that led to dissolution of the research and clinical program at CellGate using prodrugs with arginine rich transporters. Currently establishing that short oligomers of arginine can used to deliver small molecules, oligonucleotides and single antibodies to the liver as therapeutic agents for hepatitis and the eye to treat uveitis and toxoplasmosis. Show less In collaboration with Dr. Paul Wender established a real time assay monitoring the release of prodrugs inside cells and in animals. This program solves one of the key problems that led to dissolution of the research and clinical program at CellGate using prodrugs with arginine rich transporters. Currently establishing that short oligomers of arginine can used to deliver small molecules, oligonucleotides and single antibodies to the liver as therapeutic agents for hepatitis and the eye to treat… Show more In collaboration with Dr. Paul Wender established a real time assay monitoring the release of prodrugs inside cells and in animals. This program solves one of the key problems that led to dissolution of the research and clinical program at CellGate using prodrugs with arginine rich transporters. Currently establishing that short oligomers of arginine can used to deliver small molecules, oligonucleotides and single antibodies to the liver as therapeutic agents for hepatitis and the eye to treat uveitis and toxoplasmosis. Show less



Cellgate

• Pharmaceutical Manufacturing

• Founder and Chief Scientific Director

  • Sep 1998 - Sep 2004

  Led a group of 12 research scientists that resulted in the development of a novel, proprietary delivery techniques for both small molecules and biopolymers into both individual cells and tissues Led a group of 12 research scientists that resulted in the development of a novel, proprietary delivery techniques for both small molecules and biopolymers into both individual cells and tissues



Stanford University

• United States
• Higher Education
• 700 & Above Employee

• Senior Scientist

  • Sep 1996 - Sep 1998

  Developed methods for rapid introduction of biopolymers such as proteins, peptides, and oligonucleotides into a wide variety of cells. These techniques are being used in several different applications ranging from inhibiting signal transduction using dominant negative antagonists to increasing the immunogenicity of tumor antigens by transporting them into the MHC class I biosynthetic pathway in dendritic cells. In addition, developed methods to allow peptide nucleic acid conjugates to be… Show more Developed methods for rapid introduction of biopolymers such as proteins, peptides, and oligonucleotides into a wide variety of cells. These techniques are being used in several different applications ranging from inhibiting signal transduction using dominant negative antagonists to increasing the immunogenicity of tumor antigens by transporting them into the MHC class I biosynthetic pathway in dendritic cells. In addition, developed methods to allow peptide nucleic acid conjugates to be transported across biological membranes. Show less Developed methods for rapid introduction of biopolymers such as proteins, peptides, and oligonucleotides into a wide variety of cells. These techniques are being used in several different applications ranging from inhibiting signal transduction using dominant negative antagonists to increasing the immunogenicity of tumor antigens by transporting them into the MHC class I biosynthetic pathway in dendritic cells. In addition, developed methods to allow peptide nucleic acid conjugates to be… Show more Developed methods for rapid introduction of biopolymers such as proteins, peptides, and oligonucleotides into a wide variety of cells. These techniques are being used in several different applications ranging from inhibiting signal transduction using dominant negative antagonists to increasing the immunogenicity of tumor antigens by transporting them into the MHC class I biosynthetic pathway in dendritic cells. In addition, developed methods to allow peptide nucleic acid conjugates to be transported across biological membranes. Show less



ImmuLogic Pharmaceuticals

• Biotechnology

• Scientific Director

  • Sep 1989 - Sep 1995

  In collaboration with scientists at Merck Research Labs, developed an integrated research program with approximately 12 Ph.D. scientists involved in the development of small molecular weight antagonists for human MHC class II molecules This involved: the design of rapid screening assay; understanding the complex kinetics of peptide exchange involved in formation of MHC class II-peptide complexes; defining the binding requirements for peptides to this set of molecules; secondary biological… Show more In collaboration with scientists at Merck Research Labs, developed an integrated research program with approximately 12 Ph.D. scientists involved in the development of small molecular weight antagonists for human MHC class II molecules This involved: the design of rapid screening assay; understanding the complex kinetics of peptide exchange involved in formation of MHC class II-peptide complexes; defining the binding requirements for peptides to this set of molecules; secondary biological screens for the lead compounds using human T cell clones; and the development of in vivo assays using transgenic mice expressing human class II molecules. The program concluded because of the recognized need and inability to introduce the antagonists into the biosynthetic pathway of the class II molecules inside the cell. Show less In collaboration with scientists at Merck Research Labs, developed an integrated research program with approximately 12 Ph.D. scientists involved in the development of small molecular weight antagonists for human MHC class II molecules This involved: the design of rapid screening assay; understanding the complex kinetics of peptide exchange involved in formation of MHC class II-peptide complexes; defining the binding requirements for peptides to this set of molecules; secondary biological… Show more In collaboration with scientists at Merck Research Labs, developed an integrated research program with approximately 12 Ph.D. scientists involved in the development of small molecular weight antagonists for human MHC class II molecules This involved: the design of rapid screening assay; understanding the complex kinetics of peptide exchange involved in formation of MHC class II-peptide complexes; defining the binding requirements for peptides to this set of molecules; secondary biological screens for the lead compounds using human T cell clones; and the development of in vivo assays using transgenic mice expressing human class II molecules. The program concluded because of the recognized need and inability to introduce the antagonists into the biosynthetic pathway of the class II molecules inside the cell. Show less